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Background: The relationship between statin use and non-melanoma skin cancer (NMSC) is unclear with conflicting findings in
literature. Data from the Women’s Health Initiative (WHI) Observational Study and WHI Clinical Trial were used to investigate the
prospective relationship between statin use and NMSC in non-Hispanic white (NHW) postmenopausal women.
Methods: The WHI study enrolled women aged 50–79 years at 40 US centres. Among 133 541 NHW participants, 118 357 with no
cancer history at baseline and complete medication/covariate data comprised the analytic cohort. The association of statin use
(baseline, overall as a time-varying variable, duration, type, potency, lipophilicity) and NMSC incidence was determined using
random-effects logistic regression models.
Results: Over a mean of 10.5 years of follow-up, we identified 11 555 NMSC cases. Compared with participants with no statin use,
use of any statin at baseline was associated with significantly increased NMSC incidence (adjusted odds ratio (ORadj) 1.21; 95%
confidence interval (CI): 1.07–1.35)). In particular, lovastatin (OR 1.52; 95% CI: 1.08–2.16), simvastatin (OR 1.38; 95% CI: 1.12–1.69),
and lipophilic statins (OR 1.39; 95% CI: 1.18–1.64) were associated with higher NMSC risk. Low and high, but not medium, potency
statins were associated with higher NMSC risk. No significant effect modification of the statin–NMSC relationship was found for
age, BMI, smoking, solar irradiation, vitamin D use, and skin cancer history.
Conclusions: Use of statins, particularly lipophilic statins, was associated with increased NMSC risk in postmenopausal white
women in the WHI cohort. The lack of duration–effect relationship points to possible residual confounding. Additional prospective
research should further investigate this relationship.
Non-melanoma skin cancer (NMSC), which includes basal cell
carcinoma (BCC) and squamous cell carcinoma (SCC), is the most
common cancer in the United States and is responsible for
significant economic costs (Rogers et al, 2010; National Cancer
Institute, 2012). Although NMSC is more common among men
than women, the incidence has rapidly increased for both genders
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(Christenson et al, 2005; Rogers et al, 2010). Well-established
NMSC risk factors include ultraviolet radiation from sun or
tanning bed exposure (Gallagher et al, 1995; van Dam et al, 1999),
increasing age (Gray et al, 1997; Karagas et al, 1999), immuno-
suppression (particularly for SCCs) (Lichter et al, 2000), and light
skin (Hussain et al, 2009).
In laboratory studies, statins (3-hydroxy-3 methylglutaryl
coenzyme A, HMG-CoA reductase inhibitors) have appeared to
protect against NMSC by causing apoptosis of keratinocytes by
lowering cellular cholesterol levels (Gniadecki, 2004) and activating
the RAFMEK (mitogen-activated protein kinase 1) pathway (Wu
et al, 2004). Furthermore, cholesterol depletion because of statin
use has been shown to inhibit the Hedgehog signaling pathway
(Cooper et al, 2003; Corcoran and Scott, 2006), which is critical in
the carcinogenesis of basal cell carcinoma (Tang et al, 2007; Von
Hoff et al, 2009). Statins have also been shown to inhibit cancer
cells in animal models and in vitro (Chan et al, 2003). However,
statins also have immunomodulatory properties including increas-
ing regulatory T cells, which may lead to an increased risk for
NMSC (Curiel, 2007; Jang, 2008; Mausner-Fainberg et al, 2008;
Goldstein et al, 2009a,b). Additionally, statins have been associated
with increased photosensitivity, which may be due to their effect on
signal-transduction pathways leading to proinflammatory cyto-
kines (Zhang and Elmets, 2010).
Clinical studies have also reported inconsistent relationships
between NMSC and statin use. Several large retrospective studies
and a meta-analysis of randomised controlled trials (RCTs) found
no significant relationship between statins and NMSC incidence
(Bjerre and LeLorier, 2001; Asgari et al, 2009; Haukka et al, 2010;
Li et al, 2014). An analysis of three statin RCTs designed to
examine cardiovascular outcomes also found no increased risk of
skin cancer incidence (Peto et al, 2008), whereas other studies
(both observation and case–control) have found lower incidence of
NMSC and/or overall skin cancer in statin users (Blais et al, 2000;
Graaf et al, 2004). On the other hand, several reviews and RCTs
have found an increased incidence of NMSC and/or melanoma
with statin use (Scandinavian Simvastatin Survival Study Group,
1994; Collins et al, 2002; Kuoppala et al, 2008).
To contribute further to this literature, we investigated the
prospective relationship between NMSC and statin use among
postmenopausal white women in the Women’s Health Initiative
(WHI) Clinical Trial (CT) and WHI Observational Study (OS).
Given the high NMSC incidence, especially in older populations,
and 2013 cholesterol management guidelines, which are expected
to broaden statin use to B56 million people in the United States,
including patients without known cardiovascular disease (Stone
et al, 2014), it is important to further understand this relationship.
MATERIALS AND METHODS
Design, setting, and participants. The WHI was designed to
study morbidity and mortality in postmenopausal women through
a large OS and a set of CTs, including diet modification (DM),
hormone therapy (HT), and calcium and vitamin D (CaD), as
described previously (WHI Investigators, 1998). In brief, women
were recruited between 1993 and 1998 at 40 US clinical centres
with the following eligibility criteria: age 50–79 years, postmeno-
pausal, estimated survival of at least 3 years, and no plans to move
away from the recruitment area within 3 years. The combined
OSþCT multiethnic cohort included 161 808 women. For our
analyses, we included only white women owing to the low number
of skin cancer cases in other ethnicities, which reduced the analytic
cohort size to 133 541. We then excluded participants who lacked
follow-up time and medication information at baseline, had
personal cancer history at baseline (including NMSC and
melanoma), and were missing confounders in the scientific model;
this resulted in a final cohort size of 118 357 women (Figure 1).
Measurement of exposures and confounders. For measurement
of statin use, participants were instructed to bring prescription
medication containers to the baseline screening interview.
Medication names were entered into the database by interviewers.
Statin use was also updated at years 1, 3, 6, and 9 for CT
participants, and year 3 for OS participants using the same
methodology. OS women were followed until year 6 and CT
women were followed until year 9 because of low number of
medication inventories due to study closeout.
Statins were defined as any HMG-CoA reductase inhibitors, and
classified based on potency and lipophilicity/hydrophilicity accord-
ing to a prior WHI study on statin use and melanoma (Jagtap et al,
2012). Lipophilic statins included lovastatin, simvastatin, fluvasta-
tin, and cerivastatin. Hydrophilic statins included atorvastatin,
pravastatin, and rosuvastatin. Potency was defined as follows: low –
lovastatin, fluvastatin; medium – pravastatin; high – simvastatin,
atorvastatin, cerivastatin, rosuvastatin. A small percentage (o1%)
of participants used more than one statin drug; among these
participants, the analysis duration of statin use was equal to the
duration for the drug used for the longest duration time.
Potential confounders were included as covariates in the
scientific model and defined a priori based on hypothesised and
established factors for NMSC development. Information on
confounders was collected through baseline questionnaires, and
WHI OS+CT
N = 161 808
White ethnicity
N = 133 541
No history of cancer at
baseline
N = 130 303
Has follow-up time, medication
information at baseline
N = 133 032 
Not missing variable in
scientific model
N = 118 357
Figure 1. Sample size for WHI OSþCT analytic cohort.
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included the following: age group at screening (50–59, 60–69, and
70–79), education (phigh school diploma/GED, school after high
school, college degree or higher), body mass index (BMI) (o25,
X25–30, and 430 kgm 2), smoking status (never, past, and
current), vitamin D intake (o200, 200–o400, 400–o600, and
X600 IU), solar irradiance of region in Langleys (300–325, 350,
375–380, 400–430, and 475–500), geographic region by latitude
(Southern: o351N; Middle: 35–401N, and Northern: 4401N),
total physical activity (METs per week, quartiles), current health-
care provider (yes/no, as proxy for access to medical care),
adjustment for assignment to CT (active vs placebo arms of DM,
HT conjugated equine Oestrogens and oestrogenþ progestin
(EþP), and calciumþ vitamin D (CaD) trials) or OS, use of oral
contraceptives, and use of menopausal HT.
Classification of cases (follow-up and ascertainment). Non-
melanoma skin cancer cases were self-reported through ques-
tionnaires (every 6 months for CT and every year for OS) and not
centrally adjudicated. Basal cell carcinoma and SCC were not
reported separately. Over 10.5 average years of follow-up through
August 2009, 11 555 NMSC cases were identified: 1529 among
statin users and 10 026 among non-statin users.
Statistical analysis. The primary outcome of interest was devel-
opment of first-ever NMSC. We used random-effects logistic
regression models to estimate odds ratios (ORs) and 95%
confidence intervals (CIs) for NMSC incidence in relation to
statin use, as time to diagnosis data was not available for self-
Table 1A. Baseline characteristics of the WHI OSþCT cohort
Statin use at baseline
No
(N¼120584)
Yes
(N¼9719)
Characteristic N (%) N (%)
Age group (missing N¼0)
o50–59 39 519 (32.77) 1598 (16.44)
60–69 54 232 (44.97) 5114 (52.62)
70–79þ 26 833 (22.25) 3007 (30.94)
Education (missing N¼836)
oHS 4004 (3.34) 477 (4.94)
HS 20 824 (17.38) 2094 (21.69)
4HS 94 983 (79.28) 7085 (73.37)
Smoking status (missing N¼1562)
Never smoked 59 758 (50.15) 4544 (47.41)
Past smoker 51 509 (43.23) 4495 (46.90)
Current smoker 7889 (6.62) 546 (5.70)
Category of vitamin D intake (dietaryþ supplements)
(missing N¼250)
o200 42 500 (35.31) 3302 (34.02)
200–o400 22 542 (18.73) 1683 (17.34)
400–o600 30 480 (25.33) 2627 (27.07)
600þ 24 826 (20.63) 2093 (21.57)
Alcohol consumption (missing N¼814)
Non-drinker 30 313 (25.30) 2898 (29.98)
o1 drink per week 39 668 (33.11) 3347 (34.63)
1–o7 drinks per week 33 876 (28.27) 2378 (24.60)
7þ drinks per week 15 966 (13.32) 1043 (10.79)
BMI category (missing N¼1133)
o25 45 354 (37.94) 2458 (25.50)
25–30 41 257 (34.52) 3870 (40.15)
30þ 32 920 (27.54) 3311 (34.35)
Physical activity (MET-hrs/week)
p2.3 27 365 (23.91) 2257 (23.88)
42.3–8.3 27 613 (24.13) 2473 (26.16)
48.3–17.8 29 559 (25.83) 2504 (26.49)
417.8 29 920 (26.14) 2219 (23.47)
Current care provider (missing N¼1034)
Yes 112684 (94.20) 9508 (98.58)
No 6940 (5.80) 137 (1.42)
Hormone therapy status (missing N¼99)
Never used 49.997 (41.49) 4322 (44.53)
Past user 19 214 (15.95) 1739 (17.92)
Current user 51 287 (42.56) 3645 (37.55)
Oral contraceptive use (missing N¼1)
Yes 51793 (42.95) 3369 (34.66)
No 68798 (57.05) 6352 (65.34)
Langleys of exposure (missing N¼0)
300–325 38 806 (32.18) 3328 (34.24)
350 25 304 (20.98) 2084 (21.44)
375–380 13 328 (11.05) 1048 (10.78)
400–430 19 130 (15.86) 1399 (14.39)
475–500 24 016 (19.92) 1860 (19.14)
Latitude region (missing N¼0)
Northern (4401N) 58 087 (48.17) 4771 (49.09)
Middle (437–401N) 23 045 (19.11) 1838 (18.91)
Southern (p371N) 39 452 (32.72) 3110 (32.00)
Baseline NSAID use (missing N¼ 0) 46 498 (38.56) 5313 (54.67)
Skin reaction to the sun (missing N¼64041)
No change/tans but does not burn 21 963 (36.02) 2047 (38.72)
Burns, then tans 15 575 (25.54) 1183 (22.38)
Burns, tans minimally 16 499 (27.06) 1360 (25.73)
Burns, does not tan 6939 (11.38) 696 (13.17)
Table 1A. ( Continued )
Statin use at baseline
No
(N¼120584)
Yes
(N¼9719)
Characteristic N (%) N (%)
Daily summer sun exposure as a child (missing N¼62950)
o30min 1457 (2.35) 128 (2.38)
30min to 2 h 16168 (26.09) 1433 (26.64)
42h 44349 (71.56) 3818 (70.98)
Daily summer sun exposure as an adult (missing N¼62906)
o30min 19 051 (30.73) 1905 (35.26)
30min to 2 h 30944 (49.91) 2610 (48.32)
42h 12000 (19.36) 887 (16.42)
Sunscreen use (missing N¼64647)
None 28541 (47.23) 2569 (49.17)
SPF 2–14 2988 (4.94) 242 (4.63)
SPF 15–24 18308 (30.30) 1540 (29.47)
SPF 25þ 10594 (17.53) 874 (16.73)
Calcium/Vitamin D Trial Arm
Not randomised to CaD 92577 (76.77 7805 (80.31
Intervention 13 978 (11.59 963 (9.91
Control 14 029 (11.63 951 (9.78
HT Trial Arm
Not randomised to HT 100203 (83.10) 8168 (84.04)
E-alone intervention 3686 (3.06) 301 (3.10)
E-alone control 3703 (3.07) 334 (3.44)
EþP intervention 6642 (5.51) 478 (4.92)
EþP control 6350 (5.27) 438 (4.51)
DM Trial Arm
Not randomised to DM 83681 (69.40) 7255 (74.65)
Intervention 14 755 (12.24) 967 (9.95)
Control 22 148 (18.37) 1497 (15.40)
OS cohort 69 189 (57.38) 6054 (62.29)
Abbreviations: BMI¼body mass index; CaD¼ calcium and vitamin D; CT¼Clinical
Trial; DM¼diet modification; EþP¼oestrogenþprogestin; HS¼higher secondary;
HT¼ hormone therapy; OS¼Observational Study; WHI¼Women’s Health Initiative.
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reported data. A random-effects model allows us to appropriately
model the correlation between women’s repeated NMSC reports.
We fit two models, age- and study-arm-adjusted and multi-
variable-adjusted, which adjusted for the confounders listed above.
We fit several models estimating ORs for NMSC as a function of
these parameters of statin use separately: (1) any statin use, (2) type
of statin (as defined earlier in the Materials and Methods section),
(3) statin potency, (4) statin category, and (5) duration of statin use
in years (none, o1, 1 to o3, X3, o5, and X5). The primary
exposure of interest was any statin use, and all others were
considered of secondary interest. As such, all secondary P-values
were adjusted using the Bonferroni correction to control the
family-wise error rate. Each P-value was multiplied by a factor of 4
to account for the four secondary exposures. All tests were two-
sided and tested at the 0.05 level of significance.
In the primary model with any statin use as the exposure, we
formally tested for effect modification in separate models for each
potential effect modifier by using a Wald test to obtain an omnibus
P-value for the statistical interaction term. We tested six
prespecified variables: age (50–59, 60–69, 70–79 years), BMI
(o25, X25–30, and X30 kgm 2), smoking (never, former, and
current), solar irradiance Langleys (p375 and4375), and vitamin
D intake (o400 and X400 IU).
As a post hoc sensitivity analysis, we analysed the relationship
between NMSC and statin use at baseline using propensity score
matching (PSM). Variables included for matching in the propensity
score were defined a priori based on factors that may affect a
participant’s propensity for using statins, but were not likely to be
affected by statin use itself: health status, age, access to regular
medical, current health-care provider, recent pap smear, recent
mammogram, income, occupation, education, marital status,
physical activity, smoking, vitamin D use, use of oral contraceptives,
use of postmenopausal hormonal therapy, solar irradiance in
Langleys, latitude, US region, family history (skin cancer, other
cancer, MI, diabetes, stroke), osteoporosis history, arthritis history,
multivitamin use, history of fracture before the age of 55 years, and
CT arms. Propensity was determined by modelling the likelihood of
statin use at baseline as a function of the above variables using a
logistic regression models. The predicted log ORs resulting from this
model were used at propensities. We used these propensities in the
Matching package (Sekhon, 2011) in R to implement a 1 to 1
matching scheme where all baseline statin users were matched with
a single baseline non-user with the nearest propensity for statin use.
The PSM data set was then fit to a conditional logistic regression
model grouping on matched pairs. All statistical analyses were
completed using SAS 9.3 (SAS Institute, Cary, NC USA) or R 3.1.0
(R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
The baseline characteristics of the study cohort are presented in
Table 1A, stratified by use of statins at baseline. In general, statin
users were older, had higher BMI distributions, and were more likely
to have a current health-care provider. Other baseline characteristics
were similarly distributed between the two groups. At baseline, 7.5%
of the cohort used statins (8.1% in OS and 6.7% in CT); this
increased to 13.5% in the OS at year 3 and 18.6% in the CT at year 6
(Table 1B). At baseline, the most commonly used statins in the WHI
OSþCT were simvastatin (30.7%), followed by lovastatin (27.5%),
pravastatin (22.3%), fluvastatin (12.0%), and atorvastatin (8.2%)
(Table 2). Cerivastatin and rosuvastatin were not used at baseline
(not on the market at that time) but were reported in follow-up
questionnaires in subsequent years. Low potency statins were used
by 39.0% of the cohort, compared with 22.2% for medium potency
statins, and 38.8% of the cohort for high potency statins. Lipophilic
statins were used by 69.8% of the cohort. The distribution of statin
use characteristics was similar among OS and CT participants.
In our study cohort, any use of statins (primary hypothesis, as a
time-varying variable) in the random-effects logistic regression
model was associated with significantly increased NMSC incidence
(OR 1.21; 95% CI: 1.07–1.35; Table 3). Secondary analyses were
adjusted for multiple testing using the Bonferroni correction method
as described in the Materials and Methods section. For the
secondary hypothesis of statin type, increased risk was found only
for lovastatin (OR 1.52; 95% CI: 1.08–2.16) and simvastatin (OR
1.38; 95% CI: 1.12–1.69). Low (OR 1.33, 95% CI: 1.02–1.74) and
high potency statins (OR 1.20; 95% CI: 1.06–1.37) had an increased
risk compared with non-statin users. Additionally, lipophilic statin
users had a significant increase compared with non-statin users (OR
1.39; 95% CI: 1.18–1.64). There was no clear trend in duration of
use; participants using statins foro3 years had a significant increase
in odds of NMSC compared with never users; however, those using
statins for 43 years were not significantly different compared with
never users. In the secondary analyses, there was no statistically
significant effect modification found for the relationship between
any statin use and NMSC incidence for the prespecified subgroup
(age, BMI, smoking, Langleys, vitamin D; Table 4).
As a post hoc sensitivity analysis, we conducted a PSM analysis
to reanalyse the relationship between statin use and NMSC
Table 1B. Percentage of WHI OSþCT cohort reporting statin
use at study year
Cohort Baseline (%)
Year
1 (%)
Year
3 (%)
Year
6 (%)
Year
9 (%)
OSþCT 7.5% 9.5% 12.9% 18.6% 5.1%
OS 8.1% 13.5%
CT 6.7% 9.5% 12.2% 18.6% 5.1%
Abbreviations: CT¼Clinical Trial; OS¼Observational Study; WHI¼Women’s Health
Initiative. Note: WHI OS followed until Year 6 ayd WHI CT followed until Year 9 because
of study close-out.
Table 2. Baseline statin use characteristics of the WHI
OSþCT
OS
(N¼75243)
CT
(N¼55202)
OSþCT
(N¼131872)
Statin use at baseline 6054 8.1% 3665 6.7% 9719 7.5%
Type
Atorvastatin 564 9.3% 229 6.2% 793 8.2%
Fluvastatin 722 11.9% 446 12.2% 1168 12.0%
Lovastatin 1565 25.9% 1104 30.1% 2669 27.5%
Pravastatin 1349 22.3% 819 22.3% 2168 22.3%
Simvastatin 1873 30.9% 1106 30.2% 2979 30.7%
Cerivastatin 0 0.0% 0 0.0% 0 0.0%
Rosuvastatin 0 0.0% 0 0.0% 0 0.0%
Potency
Low 2273 37.6% 1521 41.5% 3794 39.0%
Medium 1345 22.2% 811 22.1% 2156 22.2%
High 2436 40.2% 1333 36.4% 3769 38.8%
Category
Lipophilic 4150 68.6% 2638 72.0% 6788 69.8%
Other 1904 31.5% 1027 28.0% 2931 30.2%
Duration
o1 year 1898 31.4% 1294 35.3% 3192 32.8%
1–o3 years 2062 34.1% 1213 33.1% 3275 33.7%
3–o5 years 1016 16.8% 598 16.3% 1614 16.6%
5þ years 1078 17.8% 560 15.3% 1638 16.9%
Abbreviations: CT¼Clinical Trial; OS¼Observational Study; WHI¼Women’s Health
Initiative. Notes: Cerivastatin and rosuvastatin are classified as high potency statins.
Cerivastatin was classified as lipophilic and rosuvastatin as other. Neither statin was used by
the cohort at baseline but both are reported in subsequent years.
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incidence, as detailed in the Materials and Methods section. This
analysis matched women who used statins with women who did
not use statins (but had a similar propensity to use statins), and
compared the outcomes between the matched pairs. The PSM
analysis was based on ‘any statin use’ and cohort characteristics at
study baseline, and did not find a significant relationship between
NMSC incidence and statin use.
DISCUSSION
In our large cohort of postmenopausal white women, use of statins
was associated with an increased incidence of all NMSC. In
particular, after adjusting P-values to account for testing of
multiple secondary hypotheses on statin type and potency,
increased risk was found for lovastatin and simvastatin statin
types only, which was consistent with our finding of an increased
risk for lipophilic statins, low potency, and high potency statins.
There was no clear association for duration of use. There was also
no significant effect modification for the relationship between
NMSC and statin use by age, BMI, smoking, Langleys, vitamin D
use, or history of NMSC/melanoma. To our knowledge, this is the
first study to examine the relationship between statin use and all
NMSC in a prospective cohort setting.
Comparison with other studies. The first two simvastatin trials
suggested an association with NMSC seen more often in treatment
groups (Mascitelli et al, 2010). Other prior clinical studies on the
relationship between NMSC and statins have been somewhat
limited and conflicting, ranging from no significant relationship
(for either all NMSCs or BCC/SCC) (Bjerre and LeLorier, 2001;
Asgari et al, 2009; Haukka et al, 2010; Li et al, 2014), increased risk
with statin use (Scandinavian Simvastatin Survival Study Group.,
1994; Collins et al, 2002; Kuoppala et al, 2008; Arnspang et al,
2014), to decreased risk with statin use (Blais et al, 2000; Graaf
et al, 2004; Peto et al, 2008). Few prospective studies have been
conducted to investigate the relationship between statin use and
either BCC or SCC, particularly with as many participants and
cases as our study. However, several large studies have suggested an
increased risk of NMSC associated with statin use. One study that
showed an increased risk with statin use and NMSC incidence was
a meta-analysis of all cancers and statins (median RR 1.6, range
1.2–2, evidence strength moderate) (Kuoppala et al, 2008); this
analysis included RCTs, cohort studies, and case–control studies. It
was also reported that NMSC was observed more often in the
treatment groups of two simvastatin trials, the Scandinavian
Table 3. ORs ratios for NMSC and statin use in the WHI OSþCT
Age and study arm adjusted Multivariable-adjusted
Statin use variable Cases Incidence per 1000 person-years OR 95% CI P-value OR 95% CI P-value
Any statin usea 0.101 0.002
No 10 026 14.0 Ref Ref
Yes 1529 15.6 1.09 0.98–1.21 1.21 1.07–1.35
Type of statin 0.400 0.080
None 10 026 14.0 Ref Ref
Atorvastatin 514 15.4 0.99 0.85–1.16 1.10 0.93–1.30
Fluvastatin 113 14.0 0.94 0.64–1.39 1.03 0.68–1.56
Lovastatin 192 15.6 1.46 1.06–2.01 1.52 1.08–2.16
Otherb 33 17.9 0.90 0.49–1.66 0.90 0.47–1.72
Pravastatin 241 15.4 0.99 0.76–1.29 1.05 0.78–1.39
Simvastatin 436 16.3 1.25 1.03–1.51 1.38 1.12–1.69
Statin potency 0.944 0.044
None 10 026 14.0 Ref. Ref.
Low 305 15.0 1.22 0.97–1.54 1.33 1.02–1.74
Med 241 15.4 0.99 0.77–1.27 1.05 0.79–1.40
High 983 15.8 1.09 0.96–1.22 1.20 1.06–1.37
Statin category 0.108 0.001
None 10 026 14.0 Ref. Ref.
Lipo 772 15.8 1.22 1.05–1.41 1.39 1.18–1.64
Other 757 15.4 0.99 0.87–1.14 1.10 0.95–1.28
Duration of use 1.000 0.116
None 10 026 14.0 Ref. Ref.
o1 417 15.3 1.12 0.94–1.33 1.22 1.01–1.49
1–o3 558 15.7 1.11 0.95–1.29 1.23 1.04–1.47
3–o5 291 15.6 1.01 0.82–1.24 1.11 0.88–1.38
5þ 263 15.8 1.10 0.88–1.37 1.23 0.97–1.57
Abbreviations: BMI¼body mass index; CI¼ confidence interval; CT¼Clinical Trial; NMSC¼ non-melanoma skin cancer; OR¼odds ratio; OS¼Observational Study; WHI¼Women’s Health
Initiative. Fully adjusted models were adjusted for age, study arm, educational attainment, BMI, smoking history, vitamin D consumption, sun exposure, physical activity, health-care provider,
occupation, and hormone use history. Bold denotes significance.
aStatin use is the primary hypothesis, tested at a¼ 0.05. Analyses on statin type, potency, category, and duration were secondary hypotheses and adjusted for multiple testing using the
Bonferroni method.
bIncludes cerivastatin and rosuvastatin. These statins were used by a very small percentage of women and never at baseline.
Table 4. Effect modification for NMSC incidence and any
statin use
Effect modifier P-value
Age 0.353
BMI 0.388
Smoking 0.979
Langleys 0.326
Vitamin D category 0.063
Abbreviations: BMI¼body mass index; NMSC¼ non-melanoma skin cancer.
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Simvastatin Survival Study (4S) and the Heart Protection Study
(HPS), with the relationship statistically significant if both studies
were combined (Scandinavian Simvastatin Survival Study Group,
1994; Collins et al, 2002) This agrees with our finding of a
substantial increase in NMSC risk being seen for simvastatin
specifically. One record-linkage study of over 400 000 Finnish
participants did not find an overall association with statin use and
NMSC, but found an increased risk associated with pravastatin
specifically (Haukka et al, 2010). A nationwide case–control study
in Denmark also found significantly increased risk of BCC only
with ever statin use among 38 484 cases (OR 1.09; 1.06–1.33),
which the authors attributed to possible residual confounding
(Arnspang et al, 2014). A prior WHI analysis found no significant
evidence for statin use as a risk factor for melanoma (Jagtap et al,
2012). In addition to these reports, the relationship of NMSC with
statin use has been assessed in retrospective and case–control
studies with mixed results (Blais et al, 2000; Graaf et al, 2004;
Asgari et al, 2009; Haukka et al, 2010; Arnspang et al, 2014).
One plausible biological mechanism for increased NMSC risk with
statin use is immunomodulation leading to increased regulatory T
cells (Curiel, 2007; Jang, 2008; Mausner-Fainberg et al, 2008;
Goldstein et al, 2009a,b). However, multiple molecular pathways
have also been proposed for how statins could decrease NMSC risk
(Cooper et al, 2003; Gniadecki, 2004; Wu et al, 2004; Corcoran and
Scott, 2006; Tang et al, 2007; Von Hoff et al, 2009), and alternative
biological mechanisms warrant further study. The literature has also
reported photosensitivity and cutaneous side effects associated with
statins, which may be related to increased NMSC risk, although the
mechanisms are also not well understood (Rodriguez-Pazos et al,
2010; Nardi et al, 2011; Toth et al, 2012).
Sensitivity analysis. In a post hoc PSM analysis conducted as a
sensitivity analysis, the use of statins was no longer found to be
significantly associated with NMSC incidence. However, the PSM
analysis examined outcomes of matched pairs based on a propensity to
use statins rather than statin use itself. In contrast, the main analysis,
which investigated actual statin use and adjusted for measures of
health access, found a significant relationship between NMSC
incidence and statin use. Additionally, the PSM analysis was based
on characteristics at study baseline; however, statin use increased
considerably during the course of the trial, which was accounted for in
the main analysis only. The conflicting findings of the main analysis
with the PSM analysis suggest other possible contributors to our
findings of increased NMSC incidence with statin use, which may be
related to characteristics of women with a propensity to use statins
(including better medical surveillance and access to care). However,
our main analysis and our sensitivity analysis using PSM accounted for
measures of socioeconomic status including current health-care
provider and education. A randomised trial of statin use would
control for such characteristics of users and non-users.
Strengths and limitations. The strengths of this study include the
large size and geographic distribution of cohort, prospective nature
of the study (given the rarity of prospective studies on this
relationship), large size of the cohort and number of NMSC cases,
and detailed information on confounders and exposures including
statin use (including duration and type). Although factors such as
age, BMI, smoking, solar irradiance, and vitamin D intake did not
significantly modify the relationship of NMSC with statin use, the
fact that our study took these into account is another strength.
Limitations of the study include the fact that the study was
observational in nature, NMSC was self-reported (not centrally
adjudicated) and not further broken down into BCC and SCC, time
to event data was not collected, and statin use was self-reported
and relatively low at baseline. In addition, we limited the analyses
to white women because of the small sample size (and thus
potential number of NMSC cases) in other ethnicities, limiting
generalisability of the findings to ethnicities where NMSC is not as
prevalent. We were also not able to fully adjust for sun exposure
because of limitations in the data collection, but we adjusted for
proxies of exposure including Langleys and geographic area.
Additionally, the lack of duration–effect relationship found for
statin use and NMSC incidence (particularly effect found for those
treated o1 year) points to the possibility of residual confounding.
CONCLUSIONS
In conclusion, the use of statins was associated with increased NMSC
risk in our cohort of postmenopausal white women. As statin use is
likely to increase significantly in the future under the new statin use
guidelines and NMSC is already the most common cancer in the
United States, these results may be important and warrant further
investigation. As these observations do not provide evidence of
causality or that a side effect of statin use is increased NMSC, we are
not suggesting changes in current statin recommendations. Regard-
less, preventive sun exposure measures (which have been shown to be
protective against NMSC) should be recommended for statin users as
well as non-users (including sunscreen, wearing protective clothing,
and avoiding the sun during peak exposure times). Patients at high
risk for NMSC because of personal/family history, medical comorbid-
ities, or skin type may want to consider using a statin type that is less
strongly associated with NMSC incidence. Further areas for
investigation include studying this relationship in the setting of a
randomised controlled trial (including the effects of specific statin
types on BCC and SCC separately), the effect of protective sun
exposure behaviors on this relationship, and the underlying biological
mechanisms that may mediate increased NMSC risk from statin use.
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